Geron (GERN) to Release Earnings on Wednesday

Key Points

• Geron Corporation is set to release its Q2 2025 earnings before the market opens on August 6th, with analysts projecting a loss of ($0.03) per share and revenue of $47.30 million.
• In its last reported quarter, Geron posted a loss of ($0.03) EPS, beating estimates but generating revenue significantly below expectations at $39.60 million.
• Analysts have mixed ratings for Geron with a consensus rating of "Hold" and a target price of $4.61, while some firms have recently lowered their price targets amid new coverage reports.

Geron (NASDAQ:GERN - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $47.30 million for the quarter.

Geron (NASDAQ:GERN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. Geron had a negative return on equity of 47.86% and a negative net margin of 119.54%. The firm's revenue for the quarter was up 12927.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.07) EPS. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Stock Performance

Geron stock traded up $0.02 during mid-day trading on Friday, hitting $1.17. 9,861,012 shares of the company's stock traded hands, compared to its average volume of 8,698,969. Geron has a one year low of $1.09 and a one year high of $4.84. The company has a quick ratio of 6.97, a current ratio of 7.87 and a debt-to-equity ratio of 0.44. The firm has a 50 day moving average price of $1.41 and a 200 day moving average price of $1.72. The company has a market cap of $745.20 million, a PE ratio of -5.57 and a beta of 0.73.

Institutional Investors Weigh In On Geron

An institutional investor recently raised its position in Geron stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Geron Corporation (NASDAQ:GERN - Free Report) by 8.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,372,016 shares of the biopharmaceutical company's stock after buying an additional 104,840 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.22% of Geron worth $2,182,000 as of its most recent filing with the Securities and Exchange Commission. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Scotiabank downgraded Geron from a "sector outperform" rating to a "sector perform" rating and dropped their price objective for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. The Goldman Sachs Group assumed coverage on Geron in a research note on Thursday, July 10th. They issued a "sell" rating and a $1.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $4.61.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.